Change to the Trixeo aerosphere inhaler

Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.

At the end of January 2023, Trixeo Aerosphere began transitioning to a new inhaler device (EvoCap). The most obvious change is the inhaler’s new look, now with a yellow actuator.

Other noticeable features include:

• A bigger dosage indicator display window and connected cap.  The puff indicator/dose counter is now bigger and counts with every puff. This means patients always know exactly how much medicine is left in their inhaler.
• The new inhaler (EvoCap) is similar to the Symbicort EvoCap inhaler. The cap is now connected to the inhaler to ensure the inhaler is secured when not in use and to prevent accidental actuation

The new device uses the same dosing, excipients and propellant as the previous Trixeo device

The new device is available to order from AAH, and other wholesalers as follows:

IMPORTANT TO NOTE: The clinical performance, delivered dose, posology, method of administration and maintenance of the inhaler (weekly rinsing) all remain the same.

TRIXEO PRESCRIBING INFORMATION (formoterol fumarate dihydrate/glycopyrronium/budesonide)